Weighted registration of 123I‐FP‐CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake
暂无分享,去创建一个
Andrea Ciarmiello | Duccio Volterrani | Luigi Mansi | Giuliano Mariani | A. Ciarmiello | L. Mansi | G. Mariani | D. Volterrani | C. Guidotti | G. Giovacchini | M. Del Sette | Patrizia Lazzeri | Massimo Del Sette | Giampiero Giovacchini | Claudio Guidotti | Martina Meniconi | Elena Carabelli | E. Carabelli | M. Meniconi | P. Lazzeri
[1] M Laruelle,et al. Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. , 1994, Journal of neurochemistry.
[2] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[3] Jan Booij,et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.
[4] M. Kaufman,et al. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's‐diseased striatum , 1991, Synapse.
[5] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[6] Ingeborg Goethals,et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] K Van Laere,et al. Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] P J Slomka,et al. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] Rainer Linke,et al. [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls , 2000, European Journal of Nuclear Medicine.
[10] P. Seeman,et al. The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus , 1991, Journal of neurochemistry.
[11] J. Ashburner,et al. Nonlinear spatial normalization using basis functions , 1999, Human brain mapping.
[12] J. Langston,et al. The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.
[13] Willibald Gerschlager,et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.
[14] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[15] Perry E Radau,et al. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Marc Laruelle,et al. Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions , 1994 .
[17] S J Kish,et al. [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease , 1997, Neurology.
[18] M. Brin,et al. Consensus Statement of the Movement Disorder Society on Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.
[19] Vesna Sossi,et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.
[20] Jan Booij,et al. Iodine-123-N-ω-Fluoropropyl-2β-Carbomethoxy-3β-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson's Disease , 1998 .
[21] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[22] Manuel Desco,et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans , 2003, NeuroImage.
[23] W. Poewe. Clinical measures of progression in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[24] Werner Poewe,et al. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.
[25] D J Wyper,et al. Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.
[26] Colin Studholme,et al. Comparison of Statistical Parametric Mapping and SPECT Difference Imaging in Patients with Temporal Lobe Epilepsy , 2002, Epilepsia.
[27] L. Deecke,et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] D. Jennings,et al. Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients , 2007, Journal of Nuclear Medicine.
[29] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[30] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[31] P B Hoffer,et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] Colin Studholme,et al. Normalized entropy measure for multimodality image alignment , 1998, Medical Imaging.
[33] Irène Buvat,et al. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] V. Poutanen,et al. Accuracy of a registration procedure for brain SPET and MRI: phantom and simulation studies. , 1997, Nuclear medicine communications.
[35] P B Hoffer,et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] R. Djaldetti,et al. Residual striatal dopaminergic nerve terminals in very long‐standing Parkinson's disease: A single photon emission computed tomography imaging study , 2011, Movement disorders : official journal of the Movement Disorder Society.
[37] N. Verhoeff,et al. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] E. Tolosa,et al. Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .
[39] C. Halldin,et al. Molecular Imaging of the Dopamine Transporter , 2010, The Journal of Nuclear Medicine.
[40] M Koole,et al. MRI guided segmentation and quantification of SPECT images of the basal ganglia: a phantom study. , 2001, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.
[41] O. Pogarell,et al. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years , 2001, Nuclear medicine communications.
[42] G Bravo,et al. Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: toward the integration of two traditions. , 1991, Journal of clinical epidemiology.
[43] Piero Calvini,et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[44] J. Seibyl,et al. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] Eileen O. Smith,et al. Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.
[46] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[47] J. Booij,et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease , 2001, Journal of Neural Transmission.
[48] A Pupi,et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. , 2002, European journal of nuclear medicine and molecular imaging.
[49] P J Slomka,et al. Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. , 2001, Medical physics.
[50] J. Seibyl,et al. Do dopamine agonists or levodopa modify Parkinson's disease progression? , 2002, European journal of neurology.
[51] Karl J. Friston,et al. Voxel-Based Morphometry—The Methods , 2000, NeuroImage.
[52] Jean-Luc Anton,et al. Region of interest analysis using an SPM toolbox , 2010 .